These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20707884)

  • 1. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.
    van Lier A; van Hoek AJ; Opstelten W; Boot HJ; de Melker HE
    BMC Health Serv Res; 2010 Aug; 10():237. PubMed ID: 20707884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
    BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
    BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
    Belchior E; Lévy-Bruhl D; Le Strat Y; Herida M
    Hum Vaccin Immunother; 2016 Sep; 12(9):2378-82. PubMed ID: 27484158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
    Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
    Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
    CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD; Pfeil AM
    Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M; Marra CA; Galanis E; Patrick DM
    Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Kim S; Choi JK; Suh J; Park SH; Lee J
    Vaccine; 2024 Jul; 42(19):4046-4055. PubMed ID: 38762358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.
    Le P; Rothberg MB
    J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of vaccination against herpes zoster.
    de Boer PT; Wilschut JC; Postma MJ
    Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.
    Coretti S; Codella P; Romano F; Ruggeri M; Cicchetti A
    Int J Technol Assess Health Care; 2016 Jan; 32(4):233-240. PubMed ID: 27624398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
    Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
    J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.